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ABSTRACT 
Elizabeth Goodall Rossitch 
The Effect of COPD on the Immune Response to Influenza Virus Vaccination 
(Under Direction of Melinda A. Beck) 
 
 Chronic Obstructive Pulmonary Disease (COPD) is a health concern worldwide 
and particularly in the United States.  It is the currently the fourth leading cause of death 
in the world and is predicted to become the third leading cause of death by 2030.  
People with COPD often experience exacerbations, an acute onset of more severe 
symptoms, caused by infections-bacterial and viral.  These exacerbations decrease 
quality of life and further disease progression.  Not to mention, while healthy individuals 
can easily recover from an influenza, it could be deadly in COPD patients.  Thus, it is 
important to ensure that individuals with COPD are adequately covered by influenza 
vaccination.  Currently, little is known about how COPD impacts the cell-mediated 
immune response, but gaining this knowledge would help determine if individuals with 
COPD are effectively covered by the vaccine. 
 The purpose of this pilot study was to determine if COPD affects the cell-
mediated immune response post influenza vaccination.  Specifically, it aimed to 
discover if the percentage of CD3+CD8+ T cells were the same in individuals with and 
without COPD.  Additionally, it aimed to assess the ability of these CD3+CD8+ T cells to 
secrete IFNγ and TNFα.  A total of 8 participants were included in the analyses of this 
study- 3 with COPD and 5 with no respiratory history.  Peripheral blood mononuclear 
cells (PBMCs) were isolated from blood samples 28-35 days post-vaccination and 
incubated for 120 hours with and without (in two separate wells) the 
3 
 
A/Victoria/361/2011.  The cells were stained for CD3, CD8, TNFα, and IFNγ using 
human fluorochrome-conjugated human antibodies. 
 There was no significant difference in the CD3+CD8+ T cell percentage between 
COPD and non-COPD groups, but the percent increase of CD3+CD8+ T cells secreting 
TNFα and IFNγ when stimulated with in vivo with A/Victoria/361/2011 was significantly 
greater in the non-COPD group.  This suggests that there might be a problem in 
CD3+CD8+ T cell function in individuals with COPD.  Therefore, there need to be 
further studies to determine whether COPD patients are adequately covered by the 
current influenza vaccination. 
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CHAPTER 1 
INTRODUCTION 
1.1 Chronic Obstructive Pulmonary Disease (COPD) 
Chronic Obstructive Pulmonary Disease (COPD) is predicted to be a worldwide 
health concern over the next few decades.  Currently it is the fourth leading cause of 
death, but the World Health Organization projects that COPD will move to third by 2030 
(3).  A literature review extracting prevalence data from 80 articles found that the United 
States had the highest COPD prevalence of 37%, compared to Japan which had the 
lowest prevalence of 0.2% (4). 
COPD is a life threatening lung disease that disrupts normal breathing through long-
term cough with mucus build up (chronic bronchitis) or destruction of the lung tissue 
over time (emphysema).  Symptoms of COPD develop slowly over time and include 
dyspnea, chronic cough, abnormal sputum, and trouble doing normal daily activities 
such as walking up a flight of stairs.  The number one risk factor for COPD is smoking 
tobacco, but other risks include certain gas or fume exposures in the workplace, 
secondhand smoke or pollution exposure, and exposure to cooking fire without proper 
ventilation (5).    
COPD cannot be cured, but symptoms can be treated via medication.  COPD 
patients can take short-acting beta-2 agonists such as Albuterol for acute symptoms 
and long-acting beta-2 agonists such as Salmeterol for long term management of 
symptoms. These medications cause bronchodilation which relieves symptoms and 
makes breathing easier. In addition, disease progression can be slowed by decreasing 
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exacerbations which aggravate the lungs, increase death in COPD patients, and 
decrease quality of life.  An exacerbation is a period (at least 48 hours) where relatively 
more severe symptoms are experienced by the patient.  So what causes these 
exacerbations?  There are several suggested causes such as non-adherence to 
medication, heart failure, pneumonia, inhalation of irritants such as tobacco smoke, and 
most notably bacterial and viral infections (3).   
1.2 Influenza Infection 
The flu season typically lasts from October to March and The Centers for Disease 
Control and Prevention (CDC) estimates that during this time 5 to 20 percent of people 
in the United States are infected with influenza (6).  This may not seem like an alarming 
statistic because many people can recover from flu without medication or complications 
(7).  Despite this, the seasonal influenza hospitalizes more than 200,000 and kills more 
than 36,000 Americans each year (6).  People at greater risk for hospitalization and 
death from influenza infection include children younger than 5 years old, older adults 
greater than 65 years old, pregnant women, and people with chronic illnesses such as 
COPD (7). 
Influenza, or flu, is a contagious viral infection, characterized by a sudden rise in 
body temperature (greater than 38.5⁰C), headache, muscle aches, fatigue, and cough 
(8).  It is transmitted person to person directly or indirectly.  Direct transmission occurs 
when an infected individual coughs, sneezes, or talks, releasing tiny virus-containing 
droplets into the air that are inhaled by the recipient via nose or mouth (6).  These 
droplets then enter the nasal and laryngeal mucosae where the virus can infect nasal 
cells, replicate, and continue spreading down into the lower airway (8).  Indirect 
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transmission occurs when the recipient touches virus from these droplets that remains 
on a surface or object and then subsequently touches their mouth, eyes or nose.  
Viruses can last on surfaces between two and eight hours depending on conditions (6).   
1.3 Cellular Immune Response to Influenza and Importance of Vaccination 
The body has several lines of defense to protect against infection, including mucus 
production to prevent it in the first place, however this paper will focus on the cell 
mediated response specifically for influenza.  When a specific strain of influenza infects 
for the first time, the body depends on the innate immune system to respond.  Later in 
the infection, the adaptive immune response responds, and unlike innate immunity, the 
adaptive immune response contains memory cells that can quickly respond to 
reinfection with the same viral strain.  The goal of vaccination is to induce the production 
of memory T cells and B cells, necessary for a rapid adaptive immune response.  Upon 
creation of these cells, the body is able to respond more quickly and effectively if the 
same pathogen infects again.  This is called a secondary immune response (9). 
Cellular immunity against influenza viral infections relies on dendritic cells, which are 
known as the antigen-presenting cells and can be found surrounding the epithelial cells 
of the airway.  When dendritic cells recognize and ingest influenza infected cells, they 
migrate to the lymphatic system where they present influenza virus-derived antigens to 
the T cells, activating them.  Specifically, CD8+ cytotoxic T cells (CTLs) recognize viral 
proteins presented in a complex with major histocompatibility complex (MHC) class I 
molecules in the dendritic cell membrane while CD4+ helper cells recognize viral 
proteins associated with MHC class II molecules in the cell membrane.  CTLs then 
migrate to the site of infection where they recognize and induce apoptosis in infected 
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cells.  They also indirectly inhibit viral replication by secreting cytokines such as 
interferon-γ (IFNγ) and tumor necrosis factor-α (TNF-α) (10). 
1.4 COPD and Influenza Virus 
If the number of COPD exacerbations were decreased, mortality rates would decline 
and quality of life would improve among COPD patients.  Since 78% of exacerbations in 
all patients admitted to the hospital were caused by a viral or bacterial infection, it is 
imperative that we aim to prevent these infections, especially in COPD patients (3).  A 
virus many of us may consider to be non-fatal could be potentially deadly in COPD 
patients.  This paper aims to determine if there are any changes in CD8+ cytotoxic T 
cell function that might make patients with COPD more susceptible to flu. 
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CHAPTER 2 
SPECIFIC AIMS AND HYPOTHESIS 
Specific Aim:  To determine if Chronic Obstructive Pulmonary Disease affects cell-
mediated immune response post influenza vaccination 
Hypothesis:  COPD will result in an impaired cell-mediated immune response.  
Specifically, I hypothesize that, following in vitro stimulation with influenza virus, fewer 
CD8+ T cells will secrete IFNγ and TNFα.  I hypothesize that the percentage of CD8+ T 
cells will be lower for individuals with COPD than individuals without COPD. 
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CHAPTER 3  
METHODS 
3.1 Study Population and Samples: 
This study population was chosen from individuals participating in a prospective 
observation study being carried out at the University of North Carolina at Chapel Hill 
Family Medicine Center.  Specifically, we targeted subjects who were followed during 
the 2012-2013 flu season.  Adults 18 years or older who were scheduled to receive the 
2012-2013 trivalent influenza vaccine (TIV) at the UNC Chapel Hill Family Medicine 
Center were eligible for participation.  Patients were excluded based on the following 
criteria: immunosuppression, self-reported use of immunomodulator or 
immunosuppressive drugs, acute febrile illness, history of hypersensitivity to any 
influenza vaccine components, history of Guilian-Barre syndrome, or use of theophylline 
preparations or warfarin (1). 
After receiving the 2012-2013 TIV in the deltoid muscle, the subject was asked to 
participate in the study. Informed consent was obtained and the study nurse measured 
each participants’ height and weight and obtained a blood sample.  The FDA approved 
the following influenza strains for inclusion in the 2012-2013 influenza vaccine: 
A/California/7/2009 (H1N1)-like virus, A/Victoria/361/2011 (H3N2)-like virus, 
B/Wisconsin/1/2010-like virus (2).  Twenty-eight to thirty-five days after receiving the 
2012-2013 influenza vaccination, participants returned to the clinic to have another 
blood sample taken.  We isolated PBMCs from the post-vaccination blood samples 
referred to here. 
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From this larger study, 25 individuals were selected for inclusion into this pilot 
study.  Fifteen of the samples (6 COPD and 9 non-COPD) were lost due to a staining 
failure on this particular plate.  Of the remaining 10 samples, 1 COPD sample and 1 
non-COPD sample were lost due to lack of cells remaining at the end of the staining 
process.  Thus, of the 8 participants that remained, 3 had a diagnosis of COPD and 5 
had no COPD diagnosis.  The medical records of patients classified as having no 
COPD diagnosis were analyzed to ensure that there was no history of any respiratory 
difficulties.  Diabetes was defined as either having a current diagnosis of diabetes or 
having no diabetes diagnosis.  Each participant was defined as either a current smoker, 
past smoker, or never a smoker.  Smoking status was self-reported by the patients. 
3.2 Peripheral Blood Mononuclear Cell Collection: 
 Post-vaccine blood samples were stored at 4⁰C and then moved to room 
temperature 30 minutes prior to the PBMC isolation process.  Histopaque-1077 was 
brought to room temperature and 3mL were aliquoted into a 15mL conical centrifuge 
tube.  Up to 8mL of whole blood was layered on top of the Histopaque-1077 and the 
conical tube was centrifuged at 400 X g for 30 minutes at room temperature.  The 
following distinct layers were identified starting from the bottom to the top: red blood 
cells, HIstopaque-1077, PBMCs, and plasma.  A pipet was used to extract the PBMC 
layer and transfer the PBMCs into a new 15mL conical centrifuge tube.  The cells were 
suspended in 10 mL sterile Hank’s Balanced Salt Solution (HBSS) and centrifuged at 
250 X g for 10 minutes at room temperature.  The supernatant was discarded and the 
cells were suspended in 5mL HBSS before being centrifuged at 250 X g for 10 minutes 
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at room temperature.  The cells were suspended in HBSS one final time (3 total washes 
in HBSS). 
 The supernatant was discarded and the cells were suspended in 500µL of Serum 
Albumin Solution that was kept at 4⁰C until use.  This solution was transferred to a 2mL 
cryogenic vial and 500µL of Freezing Medium was added dropwise.  The vials were 
placed inside isopropanol-filled Mr. Frosty containers and stored at -80⁰C for at least 
four hours.  The cells were then moved in their vials to the liquid nitrogen tank until 
thawed for specific studies. 
3.3 PBMC Thawing, Plating, and Stimulation: 
 The PBMCs from my 8 samples and a control sample (the control had received 
the 2012-2013 TIV, was 25 years old, and had a healthy weight BMI) were thawed, 
counted, and diluted with AIM-V media.  The cells were diluted to a 1X106 cells/200µL 
media solution.  From each sample, 1X106 cells were plated into two separate wells on 
96-well round-bottom plate by pipetting 200µL of solution to each of the two wells (one 
to be stimulated and one to be left unstimulated).  This held true for all the samples with 
the exception of 04-1012 and 04-1488 because there were fewer than 2X106 cells.  For 
each of these samples 1X106 cells were plated in the stimulated wells and 5.6X105 and 
6.87X105 cells were plated into the unstimulated wells for samples 04-1012 and 04-
1488 respectively.  The cells were rested for 2 hours in the incubator at 37⁰C and 5% 
CO2. 
 The plate was centrifuged at 350 X g for 5 minutes and the media was pipetted 
from the wells.  Stimulation wells received 20µL of a 1:3 dilution of live 
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A/Victoria/361/2011 (H3N2) virus and 80µL AIM-V media (a total dilution of 1:15), while 
control wells received 100µL AIM-V media.  Cell were incubated at 37⁰C and 5% CO2 
for 114 hours.  Cells were centrifuged and stimulated wells received 79µL AIM-V media, 
1µL GolgiPlug, and 20µL of the 1:3 dilution of live H3N2 virus.  Unstimulated wells 
received 99µL AIM-V media and 1µL GolgiPlug.  Cells were then incubated for 6 more 
hours at 37⁰C and 5% CO2. 
3.4 PBMC Staining and Flow Cytometry: 
 PBMCs were stained extracellularly for CD3 and CD8 and intracellularly for IFNγ 
and TNFα.  Extracellular staining was performed by spinning the cells down, removing 
the media and adding 100µL of extracellular master mix presented in Table 1 below.  
The plate was covered and incubated at 4⁰C for 30 minutes before adding 100µL of 
FACS buffer to each well and mixing.  The cells were centrifuged at 350 x g for 5 
minutes at 4⁰C and supernatant was flicked gently into the sink.  These steps were 
repeated with 200µL of FACS buffer and the cells were scraped off the bottom of each 
well. 
Table 1: Extracellular staining mix recipe per one sample 
CD3 PerCP-cy5.5 (µL) CD8 FITC (µL) FACS Buffer/FcR block 
mix (µL) 
Total Volume (µL) 
5 5 90 100 
* The FACS Buffer/ FcR block was a 1:100 dilution of FcR block 
 
 The PBMCs were then fixed and permeablized before intracellular staining.  To 
do this 100µL of Cytofix/Cytoperm was added and mixed in each well.  The plate was 
covered in foil and incubated at 4⁰C for 20 minutes.  The plate was removed from the 
refrigerator and 100µL of Perm/Wash was added and mixed in each well.  The cells 
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were centrifuged at 350 x g for 5 minutes at 4⁰C and supernatant was flicked gently into 
the sink.  The cells were washed again with 200µL Perm/Wash, centrifuged at the 
previous settings, and supernatant was removed. 
 Next the cells were stained intracellularly by adding 100µL of the master mix 
presented below in Table 2.  The plate was covered in foil and incubated at 4⁰C for 30 
minutes before.  Next 100µL of Perm/Wash was added and mixed in each well before 
covering the plate in foil and centrifuging it for 5 minutes at 350 x g and 4⁰C.  
Supernatant was removed.  Next 200µL of FACS buffer was added and mixed in each 
well, gently scraping the cells from the bottom of the well.  The plate was covered in foil 
and centrifuged at 4⁰C, 350 x g, for 5 minutes.  Supernatant was gently flicked off and 
100µL of FACS buffer was added to each well (scraping cells gently while mixing).  This 
FACS buffer was transferred to a dilution box and 100µL more of FACS buffer was 
added to each well so that any remaining cells could be scraped from the bottom of 
each well.  The FACS buffer was transferred to the same dilution box.  Each sample 
was vortexed before being analyzed using a BD Accuri Flow Cytometer and the data 
was analyzed using FlowJo. 
Table 2: Intracellular master mix recipe per one sample 
TNF-α PE (µL) IFNγ APC (µL) Perm wash (µL) Total Volume (µL) 
5 5 90 100 
 
3.5 Statistical Analysis: 
 The flow cytometry data was analyzed using JMP statistical software.  All of the 
analyses were performed using a two-tailed Kruskal-Wallis test.  A p-value of less than 
0.05 was considered to be significant. 
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CHAPTER 4 
RESULTS 
4.1 Demographics of the Study Population: 
 Participants were classified into two groups: COPD and no COPD.  The COPD 
group is characterized by individuals with a diagnosis of COPD.  The no COPD group is 
characterized by individuals who had no respiratory medical history.  The demographics 
of each participant are shown in Table 3 below. 
Table 3. Demographics of the study Population (n=8) 
Sample Sex Race Age  BMI Diabetes Smoking 
COPD  
04-1220 Female White 56 32.2 Yes  Past 
04-1348 Male White 58 27.3 Yes Current 
04-1415 Male White 72 31.2 Yes Current 
No COPD  
04-1012 Male White 65 23.1 Yes Current 
04-1342 Female White 66 19.7 No Current 
04-1371 Female White 60 29 Yes Past 
04-1399 Female White 62 27.2 No Never 
04-1488 Male White 76 25.1 No Past 
 
The average age in the COPD group was 62 ± 8.72, compared to the average 
age of 65.8 ± 6.18 in the group with no COPD.  The average BMIs for the COPD group 
and No COPD group were 30.23 ± 2.59 and 24.82 ± 3.62 respectively.   
4.2 CD3+CD8+ T Cells 
 There are no significant differences in the percentage of CD3+CD8+ T cells 
between people with COPD and people without COPD for either unstimulated or 
stimulated PMBCs (Figure 1). 
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Figure 1. There are no significant differences in the percentage of CD3+CD8+ T cells between 
people with COPD and people without COPD for either unstimulated or stimulated PMBCs 
 
 
 
4.3 CD3+CD8+IFNγ+ T Cells 
 There were no significant differences in the percentage of CD3+CD8+IFNγ+ T 
cells between people with COPD and people without COPD for either unstimulated or 
stimulated PMBCs (Figure 2).  Yet, individuals without COPD trended towards a greater 
expression of CD3+CD8+IFNγ+ T cells when comparing the stimulated samples 
between the two groups.  With the exception of one COPD participant, all individuals 
without COPD had greater CD3+CD8+IFNγ+ T cell expression than individuals with 
COPD after stimulation (Figure 3).  Despite there being no statistical differences 
between CD3+CD8+IFNγ+ T cells in people with or without COPD, we did find that the 
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percent increase between unstimulated and stimulated PBMCs from individuals with 
COPD was significantly lower for CD3+CD8+IFNγ+ T cells (Figure 4). 
 
Figure 2. There are no significant differences in the percentage of CD3+CD8+IFNγ T cells 
between people with COPD and people without COPD for either unstimulated or stimulated 
PMBCs 
 
 
Figure 3. All participants trended towards an increase in CD3+CD8+IFNγ+ T cell expression 
upon stimulation with H3N2, but individuals without COPD trended towards a greater expression 
CD3+CD8+IFNγ+ T cells after stimulation with H3N2. 
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Figure 4. Impaired upregulation of CD3+CD8+IFNγ+ T cells in PBMCs from individuals with 
COPD. 
 
4.4 CD3+CD8+TNFα+ T Cells  
Individuals with COPD had a significantly higher expression of 
CD3+CD8+TNFα+ T cells than individuals without COPD for unstimulated PMBCs.  
There was no difference between CD3+CD8+TNFα+ T cell expression in people with 
COPD compared to people without COPD for PBMCs stimulated with H3N2 (Figure 5).  
Despite this, we did find that the percent increase between unstimulated and stimulated 
PBMCs from individuals with COPD was significantly lower for CD3+CD8+TNFα+ T 
cells (Figure 6).  All participants without COPD were able to upregulate their expression 
of CD3+CD8+TNFα+ T cells when stimulated with H3N2, while individuals with COPD 
varied in their response upon stimulation.  Figure 7 shows the three different responses 
among COPD patients.  One COPD participant upregulated expression of 
CD3+CD8+TNFα+ T cells, while the other COPD participants either had downregulated 
expression or unchanged expression of CD3+CD8+TNFα+ T cells upon stimulation. 
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Figure 5. Individuals with COPD had a significantly higher expression of CD3+CD8+TNFα+ T 
Cells than individuals without COPD for unstimulated PMBCs. 
 
 
Figure 6. Impaired upregulation of CD3+CD8+TNFα+ T cells in PBMCs from individuals with 
COPD. 
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Figure 7. All individuals without COPD trended towards an increase in CD3+CD8+TNFα+ 
expression upon stimulation with H3N2, but individuals with COPD had different responses to 
stimulation. 
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CHAPTER 5 
DISCUSSION 
5.1 CD3+CD8+ T Cells 
 CD3+CD8+ T cell expression was similar in people with COPD and people 
without COPD for unstimulated PBMCs and PBMCs stimulated with H3N2.  This 
suggests that the dendritic cells are recognizing influenza virus, migrating to the 
lymphatic system, and presenting influenza virus-derived antigens to T cells properly.  
Secondly, this indicates that CD3+CD8+ T cells are being activated appropriately, but 
there might be a problem in their function that causes people with COPD to be more 
susceptible to severe complications or even death when exposed to influenza. 
5.2 CD3+CD8+IFNγ+ T Cells 
PBMCs from each participant had an increased expression of CD3+CD8+IFNγ+ 
T cells when stimulated.  In other words, PMBCs stimulated with H3N2 had more 
CD3+CD8+ T cells that were able to secrete IFNγ in response to influenza infection.  
This is important because IFNγ plays a role in inhibiting viral replication (13).  But it is 
important to note that individuals without COPD had a significantly greater percent 
increase in CD3+CD8+IFNγ+ T cell expression upon stimulating PBMCs with H3N2.  
This indicates that there might be an impairment in the function of CD3+CD8+ T cells in 
people with COPD.  Specifically, they could have impairments in the signaling pathway 
for the secretion of IFNγ in CD3+CD8+ T cells or there might be a defect in the IFNγ 
secretion pathway itself. 
5.3 CD3+CD8+TNFα+ T Cells 
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Individuals with COPD had a significantly higher expression of 
CD3+CD8+TNFα+ T cells than individuals without COPD in unstimulated PMBCs.  This 
was an expected finding because individuals with COPD have chronic systemic 
inflammation and TNFα is an important pro-inflammatory cytokine (11).  Despite this, 
individuals with COPD and individuals without COPD had a similar percentage of 
CD3+CD8+ T cells with the ability to secrete TNFα when stimulated.  So even though 
we found that individuals without COPD had a significantly greater percent increase of 
expression for CD3+CD8+TNFα+ T cells between unstimulated and stimulated PBMCs, 
the ability of CD3+CD8+ T cells to secrete TNFα may not be impaired in people with 
COPD.  Instead, maybe people with COPD have decreased sensitivity to the anti-viral 
effects of TNFα and thus TNFα is not able to contribute significantly to the inhibition of 
viral replication (12).  Or, there is a possibility that TNFα may not play a significant 
enough role in inhibiting viral replication and all of the TNFα pathways are normal in 
people with COPD. 
5.4 Limitations 
 This study had several limitations.  One of the greatest limitations of the study 
was the sample size.  There were 8 total participants, 3 participants with COPD and 5 
participants without COPD.  Thus, the groups are too small to draw true significant 
differences between.  Though we did find some significant differences, these among 
other trends observed can only point towards future research studies because of the 
small sample size.   
 An additional study limitation is that COPD status was determined based on 
medical records.  Even though we ensured that each participant had a diagnosis of 
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COPD, we could not assess the severity or chronicity of each individuals’ COPD.  
People who were diagnosed with COPD more recently might not have the same 
immune response to influenza as people who have been diagnosed for a longer period 
of time.  In other words, it may take time for some changes in the immune response to 
occur.  In addition, people without COPD were chosen based on their medical records 
indicating no history of respiratory difficulties.  Despite this, we cannot be sure that this 
person has not been seen for respiratory difficulties somewhere other than the Family 
Medicine Center or is just not reporting their symptoms to the physician.  
 Finally, the BMIs between the group with COPD and group without COPD are 
also a limitation to this study.  People with COPD had an average BMI of 30.23 ± 2.59 
and people without COPD had an average BMI of 24.82 ± 3.62.  According to the 
National Institutes of Health (NIH), a healthy weight BMI is 18.5-24.9, overweight is 
25.0-29.9, and obese is 30.0 and above (14).  This means the No COPD group is 
considered to have a healthy weight BMI while the COPD group is considered obese.  
This is problematic because previous studies show that activation and function of CD8+ 
T cells are impaired in PBMCs from overweight and obese individuals exposed to 
influenza and there is impaired upregulation of TNFα secretion in PBMC supernates 
from obese individuals (1).  So ultimately, the trends that we see here could be due to 
obesity instead of COPD. 
5.6 Study Implications and Future Studies 
 People with COPD are more susceptible to severe complications or even death 
resulting from an influenza infection (3).  Thus, we must ensure that COPD patients are 
adequately covered by the current dose of the influenza vaccine.  To ensure adequate 
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coverage, future studies should look at CD3+CD8+ T cells activation and function just 
as we did here to confirm the trends presented in this paper.  If in fact there are no 
significant differences in the percentage of CD3+CD8+ T cells between people with 
COPD and people without COPD for either unstimulated or stimulated PMBCs, it would 
be interesting to perform a study where a lung biopsy was performed in people who 
were actually infected with influenza.  Differences in the expression of CD3+CD8+ T 
cells in the lung would indicate whether there is a problem in recruiting these cells to the 
lung during infection. 
 It would also be beneficial to perform studies that looked at how smoking status 
effects the cellular immune response to influenza virus vaccination because smoking is 
the number one risk factor for COPD (3).  Because this study was not able to stratify the 
data based on smoking status, smoking could be a confounding factor in this pilot study.  
These studies would have huge clinical implications because if past-smokers had a 
similar cellular response to influenza stimulation as non-smokers or at least a better 
response than current smokers, it would give people yet another motivation to quit 
smoking. 
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